SCOPUS 정보 검색 플랫폼

1
- 77956922384
- Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
- Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7.
- (2010) JAMA , vol.304 , pp. 1350-1357
- Bhatt, D.L.¹ Eagle, K.A.² Ohman, E.M.³

2
- 65849268320
- Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials
- Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
- (2009) Lancet , vol.373 , pp. 1849-1860

3
- 0037454050
- Oral anticoagulants in patients with coronary artery disease
- Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003;41:Suppl S:62S-69S.
- (2003) J Am Coll Cardiol , vol.41 , pp. 62S-69S
- Anand, S.S.¹ Yusuf, S.²

4
- 79952496003
- Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: Pooled analysis of four studies
- Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost 2011;105:444-53.
- (2011) Thromb Haemost , vol.105 , pp. 444-453
- Turpie, A.G.¹ Lassen, M.R.² Eriksson, B.I.³

5
- 84859385808
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
- The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
- (2012) N Engl J Med , vol.366 , pp. 1287-1297

6
- 78650619315
- Oral rivaroxaban for symptomatic venous thromboembolism
- The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
- (2010) N Engl J Med , vol.363 , pp. 2499-2510

7
- 80052592404
- Rivaroxaban versus warfarin in nonvalvu-lar atrial fibrillation
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvu-lar atrial fibrillation. N Engl J Med 2011; 365:883-91.
- (2011) N Engl J Med , vol.365 , pp. 883-891
- Patel, M.R.¹ Mahaffey, K.W.² Garg, J.³

8
- 84862907587
- Rivaroxaban in patients with a recent acute coronary syndrome
- Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
- (2012) N Engl J Med , vol.366 , pp. 9-19
- Mega, J.L.¹ Braunwald, E.² Wiviott, S.D.³

9
- 85026258046
- Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anti-coagulation Strategies (COMPASS) trial
- Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anti-coagulation Strategies (COMPASS) trial. Can J Cardiol 2017;33:1027-35.
- (2017) Can J Cardiol , vol.33 , pp. 1027-1035
- Bosch, J.¹ Eikelboom, J.W.² Connolly, S.J.³

10
- 23044505564
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
- Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
- (2005) J Thromb Haemost , vol.3 , pp. 692-694
- Schulman, S.¹ Kearon, C.²

11
- 79957440872
- A mixture gatekeeping procedure based on the Hommel test for clinical trial applications
- Brechenmacher T, Xu J, Dmitrienko A, Tamhane AC. A mixture gatekeeping procedure based on the Hommel test for clinical trial applications. J Biopharm Stat 2011;21:748-67.
- (2011) J Biopharm Stat , vol.21 , pp. 748-767
- Brechenmacher, T.¹ Xu, J.² Dmitrienko, A.³ Tamhane, A.C.⁴

14
- 34447502152
- Oral anticoagulant and antiplatelet therapy and peripheral arterial disease
- The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27.
- (2007) N Engl J Med , vol.357 , pp. 217-227

15
- 0030590746
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
- (1996) Lancet , vol.348 , pp. 1329-1339

16
- 33645861080
- Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
- Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
- (2006) N Engl J Med , vol.354 , pp. 1706-1717
- Bhatt, D.L.¹ Fox, K.A.A.² Hacke, W.³

17
- 84928944621
- Long-term use of ticagrelor in patients with prior myocardial infarction
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800.
- (2015) N Engl J Med , vol.372 , pp. 1791-1800
- Bonaca, M.P.¹ Bhatt, D.L.² Cohen, M.³

18
- 85008318890
- Ticagrelor versus clopidogrel in symptomatic peripheral artery disease
- Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:32-40.
- (2017) N Engl J Med , vol.376 , pp. 32-40
- Hiatt, W.R.¹ Fowkes, F.G.R.² Heizer, G.³

19
- 84859555815
- Vorapaxar in the secondary prevention of atherothrombotic events
- Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13.
- (2012) N Engl J Med , vol.366 , pp. 1404-1413
- Morrow, D.A.¹ Braunwald, E.² Bonaca, M.P.³